How much funding has ONCOMATRYX BIOPHARMA raised?

ONCOMATRYX BIOPHARMA has raised $143.4M in total funding, most recently a Series D round.

Who are ONCOMATRYX BIOPHARMA's investors?

ONCOMATRYX BIOPHARMA's investors include Kutxa Fundazioa, European Innovation Council Fund, Asabys Partners, Basque Government, Ysios Capital, Alta Life Sciences.

Where is ONCOMATRYX BIOPHARMA headquartered?

ONCOMATRYX BIOPHARMA is headquartered in Bilbao, Spain.

What industry is ONCOMATRYX BIOPHARMA in?

ONCOMATRYX BIOPHARMA operates in Biotech, Healthcare.

How many employees does ONCOMATRYX BIOPHARMA have?

ONCOMATRYX BIOPHARMA has 11-50 employees.

ONCOMATRYX BIOPHARMA

Modulating the tumor microenvironment

Bilbao, Spain · $143.4M raised

Biotech

Healthcare

Headquarters: Bilbao
Employees: 11–50
Business Model: B2B

Total Funding: $143.4M
Last Round: $67.0M Series DMar 2026
Rounds: 5

About

Oncomatryx Biopharma is a clinical-stage biopharmaceutical company based in Bilbao, Spain, founded to modulate the tumor microenvironment rather than attack tumor cells directly. The company is developing next-generation Antibody-Drug Conjugates that target Cancer-Associated Fibroblasts in the tumor stroma to treat difficult-to-treat metastatic solid tumors, with its lead candidate OMTX705 in clinical trials since 2022. Oncomatryx has been awarded EU EIC Accelerator funding to advance its ADC platform.

Summary

ONCOMATRYX BIOPHARMA is a Biotech company based in Bilbao, Spain. It has raised $143.4M in total across 5 rounds, most recently a $67.0M Series D round in Mar 2026. Investors include Kutxa Fundazioa, European Innovation Council Fund and Asabys Partners.

LinkedIn X (Twitter)